Remdesivir impairs mouse preimplantation embryo development at therapeutic concentrations

Remdesivir (RDV) is the first antiviral drug to be approved by the US Food and Drug Administration for the treatment of COVID-19. While the general safety of RDV has been studied, its reproductive risk, including embryotoxicity, is largely unknown. Here, to gain insights into its embryotoxic potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Marikawa, Yusuke, Alarcon, Vernadeth B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122741/
https://www.ncbi.nlm.nih.gov/pubmed/35605700
http://dx.doi.org/10.1016/j.reprotox.2022.05.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122741/
https://www.ncbi.nlm.nih.gov/pubmed/35605700
http://dx.doi.org/10.1016/j.reprotox.2022.05.012

Ejemplares similares